Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab

Journal of Clinical Rheumatology

Volumn 12, Issue 6, 2006, Pages 291-293

  Atchia, Ismael I ^a   Kidd, C Elizabeth ^a   Bell, R W D ^a  

^a WANSBECK GENERAL HOSPITAL   (United Kingdom)

Author keywords

Infliximab; Necrotizing scleritis; Peripheral ulcerative keratitis; TNF alpha

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CARBOXYMETHYLCELLULOSE; CHLORAMPHENICOL; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TISSUE ADHESIVE;

ADULT; ANAMNESIS; ARTICLE; BLURRED VISION; CASE REPORT; CLINICAL FEATURE; CONTACT LENS; COUGHING; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; INTRAOCULAR PRESSURE; KERATITIS; LABORATORY TEST; MALE; OPHTHALMOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; RHEUMATOID ARTHRITIS; SCLERITIS; SEPSIS; SKIN DEFECT; THORAX RADIOGRAPHY; TUBERCULOSEPSIS; TUBERCULOSIS; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOTHERAPY; KERATITIS; MALE; MIDDLE AGED; NECROSIS; SCLERITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845492153     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000249766.24780.95     Document Type: Article

References (13)

1. Patel S, Lundy D. Ocular manifestations of autoimmune disease. Am Fam Physician. 2002;66:991-998.
2. Jabs D, Mudun A, Dunn J, et al. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130:469-476.
3. Erhardt C, Mumford P, Venables P, et al. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis. 1989;48:7-13.
4. Foster C, Forstot S, Wilson L. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984;91:1253-1263.
5. Clewes A, Dawson J, Kaye S, et al. Peripheral ulcerative keratitis in rheumatoid arthritis: successful use of intravenous cyclophosphamide and comparison of clinical and serological characteristics. Ann Rheum Dis. 2005;64:961-962.
6. Watson P, Young R. Scleral structure, organisation and disease. A review. Exp Eye Res. 2004;78:609-623.
7. Smith J, Levinson R, Holland G, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252-257.
8. Murphy C, Ayliffe W, Booth A, et al. Tumour necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.
9. Ahmadi-Simab K. Successful therapy of refractory anterior scleritis in primary Sjögren's syndrome with rituximab. Ann Rheum Dis. 2005;64:1087-1100.
10. Hernandez-Illas M, Tozman E, Fulcher S, et al. Recombinant human tumour necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye & Contact Lens: Science & Clinical Practice. 2004;30:2-5.
11. Diaz-Valle D, Miguelez Sanchez R, Fernandez Espartero M, et al. [Treatment of refractory anterior diffuse scleritis with infliximab]. Archivos de la Sociedad Espanola de Oftalmologia. 2004;79:405-408.
12. Murphy C, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.
13. Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Medical Weekly. 2002;132:414-422.